Wide Ranks

CLNN

Clene Inc.

4.15

Top Statistics
Market Cap 33 M Forward PE -1.39 Revenue Growth -66.20 %
Current Ratio 0.99 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.20 Enterprise / Revenue 93.40 Price To Sales Trailing12 Months 74.92
Profitability
Profit Margins 0.00 % Operating Margins -8121.98 %
Balance Sheet
Total Cash 21 M Total Cash Per Share 3.35 Total Debt 32 M
Total Debt To Equity Current Ratio 0.99 Book Value Per Share 2.08
All Measures
Short Ratio 190.00 % Message Board Id finmb_339429732 Shares Short Prior Month 176188
Return On Equity -2.90 City Salt Lake City Uuid c8c1753f-e5d6-313a-977a-f2458bf9394b
Previous Close 3.88 First Trade Date Epoch Utc 1 B Book Value 2.08
Beta 0.4150 Total Debt 32 M Volume 41045
Price To Book 1.99 Last Split Date 1 B Fifty Two Week Low 3.82
Total Cash Per Share 3.35 Total Revenue 442000 Shares Short Previous Month Date 1 B
Target Median Price 30.50 Max Age 86400 Recommendation Mean 1.50
Sand P52 Week Change 0.3133 Operating Margins -8121.98 % Target Mean Price 45.17
Net Income To Common -30456000 Short Percent Of Float 0.0224 Implied Shares Outstanding 7 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 110500
Average Volume10days 110500 Total Cash 21 M Next Fiscal Year End 1 B
Revenue Per Share 0.0690 Held Percent Insiders 0.2828 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 3.88
Target Low Price 20.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 5.16
Open 3.94 Free Cashflow -14459625 State UT
Dividend Yield 0.00 % Return On Assets -0.4171 Time Zone Short Name EST
Trailing Eps -5.29 Day Low 3.94 Address1 6550 South Millrock Drive
Shares Outstanding 7 M Price Hint 4 Target High Price 84.00
Website https://clene.com 52 Week Change -0.5284 Average Volume 77645
Forward Eps -3.53 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 81.60 % Last Split Factor 1:20 Regular Market Day High 4.29
Is_sp_500 False Profit Margins 0.00 % Fifty Two Week High 12.00
Day High 4.29 Shares Short 127257 Regular Market Open 3.94
Industry Key packaged-foods Earnings Growth 0.00 % Enterprise To Revenue 93.40
Revenue Growth -66.20 % Shares Percent Shares Out 0.0160 Operating Cashflow -27370000
Currency USD Time Zone Full Name America/New_York Market Cap 33 M
Is_nasdaq_100 False Zip 84121 Quote Type EQUITY
Industry Packaged Foods Long Name Clene Inc. Regular Market Day Low 3.94
Held Percent Institutions 0.1291 Current Price 4.15 Address2 Suite G50
Enterprise To Ebitda -1.20 Financial Currency USD Current Ratio 0.99
Gross Margins 81.00 % Industry Disp Packaged Foods Number Of Analyst Opinions 6
Country United States Float Shares 3 M Two Hundred Day Average 6.47
Enterprise Value 41 M Price To Sales Trailing12 Months 74.92 Forward PE -1.39
Regular Market Volume 41045 Ebitda -34400000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.

Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution.

In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles.

The company is headquartered in Salt Lake City, Utah.